• Palvella Therapeutics’ third-quarter 2026 net loss more than doubled to $24.64 million from a year earlier.
• General and administrative expenses more than tripled to $11.9 million, while research and development spending rose 66% to $10.82 million.
• Cash, cash equivalents and short-term investments totaled $236.7 million at September 30, 2026.
• The FDA accepted QTORIN rapamycin’s application for microcystic lymphatic malformations, granting priority review with a February 28, 2027 target action date.
• A standalone U.S. commercial launch is planned for the first half of 2027, subject to FDA approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050730PRIMZONEFULLFEED9870892) on November 05, 2026, and is solely responsible for the information contained therein.